Compare Immunovant Inc. Common Stock (IMVT) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs T-Mobile Us Inc — how do they compare? Immunovant Inc. Common Stock trades at $30.47 (market cap $6.25B), while T-Mobile Us Inc trades at $148.58 (market cap $183.76B). The key difference: T-Mobile Us Inc is far larger — about 29.4× Immunovant Inc. Common Stock's market cap, and T-Mobile Us Inc pays a 2.73% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 1 Days and T-Mobile Us Inc for 84 Days on average.
| IMVT | TMUS | |
|---|---|---|
Market Cap | $6.25B | $183.76B |
Volume | 1,755,411 | 4,294,650 |
Sector | Health | Media |
52-Week High | $44.96 | $230.06 |
52-Week Low | $17.03 | $161.73 |
Typical Hold Time | 1 Days | 84 Days |
Enterprise Value | $5.35B | $300.37B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TMUS trades at $171.31, up 2.2% today, with a bullish technical signal and strong analyst support. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growth to $88.31B in 2025. The company announced a 15% dividend hike and is advancing AI-driven 5G network upgrades, while maintaining robust profitability with a net margin of 11.45%.
Outlook remains positive given earnings momentum and strategic initiatives, but risks include high debt levels and competitive pressures. The consensus price target of $231.10 implies significant upside, supported by 79.6% buy ratings from analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
